Thierry Lesimple
Overview
Explore the profile of Thierry Lesimple including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
2359
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amiot M, Mortier L, Dalle S, Dereure O, Dalac S, Dutriaux C, et al.
EClinicalMedicine
. 2024 Dec;
78:102960.
PMID: 39717261
Background: Immune checkpoint inhibitors (ICIs) have demonstrated their efficacy with a 7.5-year overall survival (OS) close to 50% for advanced stages. The design of clinical trials provides for treatment until...
2.
Karine B, Mortier L, Dereure O, Dalac S, Montaudie H, Legoupil D, et al.
Br J Dermatol
. 2024 Nov;
PMID: 39605282
Background: The Checkmate 067 randomized controlled trial, published in 2015, demonstrated improved progression-free survival and numerically, although not statistically, superior overall survival for ipilimumab + nivolumab. The objective of this...
3.
Macaire C, Lefevre W, Dalac S, Montaudie H, Legoupil D, Dereure O, et al.
Melanoma Res
. 2024 Nov;
35(1):50-59.
PMID: 39527777
The link between palliative care and oncology must continue to develop, taking into account advances in treatment.Immune checkpoint inhibition (ICI) for metastatic melanoma is associated with different types of response,...
4.
Long G, Hauschild A, Santinami M, Kirkwood J, Atkinson V, Mandala M, et al.
N Engl J Med
. 2024 Jun;
391(18):1709-1720.
PMID: 38899716
Background: The 5-year results of this trial showed that adjuvant therapy with dabrafenib plus trametinib resulted in longer relapse-free survival and distant metastasis-free survival than placebo among patients with V600-mutated...
5.
Jones R, Fizazi K, James N, Tammela T, Matsubara N, Priou F, et al.
Prostate Cancer Prostatic Dis
. 2023 Oct;
27(4):786-789.
PMID: 37884613
Background: In patients with metastatic castration-resistant prostate cancer, darolutamide was well tolerated for 25 months, but minimal long-term safety data are available. Methods: Treatment-emergent adverse events (TEAEs) for patients receiving...
6.
Dummer R, Corrie P, Gutzmer R, Meniawy T, Del Vecchio M, Lebbe C, et al.
J Clin Oncol
. 2023 Jun;
41(23):3917-3929.
PMID: 37307514
Purpose: To address the paucity of data in patients with historically poor outcomes, we conducted the single-arm phase IIIb CheckMate 401 study to evaluate the safety and efficacy of nivolumab...
7.
Poizeau F, Balusson F, Lemaitre F, Tron C, Pracht M, Russo D, et al.
Br J Dermatol
. 2023 Feb;
188(4):482-490.
PMID: 36760148
Background: Proton-pump inhibitors (PPIs) are commonly used by patients with cancer, although they could reduce the absorption of oral anticancer targeted therapies. The US Food and Drug Administration states that...
8.
Kandel M, Bardet A, Dalle S, Allayous C, Mortier L, Guillot B, et al.
Curr Oncol
. 2022 Dec;
29(12):9255-9270.
PMID: 36547139
Nine drugs have been marketed for 10 years for the treatment of advanced melanoma (AM). With half of patients reaching a second line, the optimal sequence of treatments remains unclear....
9.
Robert C, Lebbe C, Lesimple T, Lundstrom E, Nicolas V, Gavillet B, et al.
Clin Cancer Res
. 2022 Dec;
29(5):858-865.
PMID: 36516188
Purpose: Androgen deprivation regenerates the thymus in adults, expanding of T-cell receptor V β repertoire in blood and lymphoid organs and tumor-infiltrating lymphocytes in human prostate tumors. In melanoma murine...
10.
Girod M, Dalle S, Mortier L, Dalac S, Leccia M, Dutriaux C, et al.
JCO Precis Oncol
. 2022 Nov;
6:e2200075.
PMID: 36356284
Purpose: Mitogen-activating protein kinase inhibitors (MAPKis) are largely used in V600E/K BRAF-mutated metastatic melanomas, but data regarding effectiveness of targeted therapy in patients with rare BRAF mutations and molecular description...